Oppenheimer initiated coverage of BridgeBio with a Perform rating and no price target The firm sees “substantial challenges ahead” for the company. BridgeBio’s two key assets, acoramidis and infigratinib, face competitive markets with entrenched players if both drugs are approved and commercialized, the analyst tells investors in a research note. Opco has limited confidence on efficacy among BridgeBio’s other pipeline assets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio completes enrollment of FORTIFY Phase 3 study of BBP-418
- Opening Day: Obesity drug developer BioAge makes Nasdaq debut
- BridgeBio presents post-hoc analysis evaluating acoramidis
- BioMarin price target lowered to $90 from $118 at Truist
- BridgeBio announces FDA granted BTD to oral infigratinib